We are live on ! Find out more
LBRX

LB Pharmaceuticals
LBRX

53 hedge funds and large institutions have $315M invested in LB Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 53 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

99.18% more ownership

Funds ownership: 0% → 99.18% (+99%)

Holders
53
Holders Change
+53
Holders Change %
–
% of All Funds
0.7%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
53
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
+$53.2M
2
RCM
RA Capital Management
Massachusetts
+$28.2M
3
TCM
TCG Crossover Management
California
+$27.7M
4
CC
Commodore Capital
New York
+$23.8M
5
LGM
Logos Global Management
California
+$17.9M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
26
Boxer Capital Management
California
$1.11M +$1.11M +70,000 New
SCM
27
Silverarc Capital Management
Massachusetts
$1.11M +$1.11M +70,000 New
HF
28
HRT Financial
New York
$928K +$933K +58,815 New
MIM
29
Monashee Investment Management
Massachusetts
$632K +$635K +40,000 New
TD Asset Management
30
TD Asset Management
Ontario, Canada
$581K +$584K +36,780 New
PD
31
Point72 (DIFC)
United Arab Emirates
$537K +$540K +34,003 New
Barclays
32
Barclays
United Kingdom
$487K +$489K +30,839 New
Jane Street
33
Jane Street
New York
$479K +$481K +30,345 New
ACP
34
Acuta Capital Partners
California
$474K +$476K +30,000 New
Hudson Bay Capital Management
35
Hudson Bay Capital Management
Connecticut
$428K +$430K +27,097 New
Squarepoint
36
Squarepoint
New York
$329K +$330K +20,825 New
OAM
37
Oxford Asset Management
United Kingdom
$280K +$282K +17,763 New
Manulife (Manufacturers Life Insurance)
38
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$276K +$277K +17,488 New
AC
39
Aristeia Capital
Connecticut
$241K +$242K +15,270 New
PAS
40
Point72 Asia (Singapore)
Singapore
$230K +$231K +14,535 New
QC
41
Quantessence Capital
New York
$225K +$226K +14,225 New
Geode Capital Management
42
Geode Capital Management
Massachusetts
$215K +$216K +13,591 New
Two Sigma Investments
43
Two Sigma Investments
New York
$213K +$214K +13,500 New
BHCM
44
Brevan Howard Capital Management
Jersey
$209K +$210K +13,259 New
JFG
45
Jefferies Financial Group
New York
$207K +$208K +13,100 New
XT
46
XTX Topco
Cayman Islands
$178K +$179K +11,276 New
LCM
47
Landscape Capital Management
New Jersey
$168K +$169K +10,638 New
Morgan Stanley
48
Morgan Stanley
New York
$152K +$152K +9,605 New
Federated Hermes
49
Federated Hermes
Pennsylvania
$142K +$143K +9,000 New
Bank of America
50
Bank of America
North Carolina
$26.8K +$27K +1,700 New
1
2
3

LBRX Hedge Fund Activity: Q3 2025 in Review

53 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in LB Pharmaceuticals (LBRX) for Q3 2025, worth a combined $315M.

Buyers outnumbered sellers: 53 funds opened new LBRX positions and 0 closed out — a net gain of 53 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Deep Track Capital, opening a new position worth an estimated $53.2M.

  • 53 institutional investors held LB Pharmaceuticals (LBRX) as of Q3 2025, up from 0 in Q2 2025.
  • Funds reported $315M of LB Pharmaceuticals stock for Q3 2025.
  • 53 funds opened new LB Pharmaceuticals positions in Q3 2025 and 0 closed out, a net change of +53 holders.
  • The largest LB Pharmaceuticals buyer in Q3 2025 was Deep Track Capital, an estimated $53.2M added.

Based on aggregated 13F filings for Q3 2025.